The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Head-to-head comparison of 68Ga-PSMA-11 PET with 99mTc-MDP bone scan for detection of bone disease in patients with prostate cancer with biochemical progression during ADT: A single center prospective study.
 
Andrei Gafita
No Relationships to Disclose
 
Rejah M. Alano
No Relationships to Disclose
 
Matthew Rettig
Leadership - Aravalent; Survalent
Stock and Other Ownership Interests - Oncovalent Therapeutics; Survalent
Consulting or Advisory Role - Ambrx; Amgen; Clovis Oncology; Inmune Bio; Roivant
Speakers' Bureau - Bayer; Johnson & Johnson
Research Funding - Johnson & Johnson (Inst); Medivation/Astellas (Inst); Novartis (Inst); Progenics
Patents, Royalties, Other Intellectual Property - I am a co-inventor on a patent for novel inhibitors of the N-terminal domain of the AR. There are NO commercial partnerships as of yet.
Travel, Accommodations, Expenses - Johnson & Johnson
 
John Shen
Consulting or Advisory Role - AstraZeneca; Bayer; Kite/Gilead; Sanofi
Research Funding - Ambrx (Inst); Arvinas (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Exelixis (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst)
Travel, Accommodations, Expenses - Bayer; Kite/Gilead; Sanofi
 
Wesley Robert Armstrong
No Relationships to Disclose
 
Tristan Grogan
No Relationships to Disclose
 
Sandy Liu
Honoraria - Eisai; EMD Serono; Exelixis; Merck; SeaGen; SeaGen
Consulting or Advisory Role - Exelixis; Exelixis; SeaGen; SeaGen; SeaGen
Speakers' Bureau - EMD Serono; Exelixis; Exelixis; SeaGen
 
Matthias R. Benz
No Relationships to Disclose
 
Johannes Czernin
Leadership - SOFIE; Trethera
Stock and Other Ownership Interests - SOFIE; Trethera
Consulting or Advisory Role - Advanced Accelerator Applications; Aktis Oncology; Amgen; Jubilant Radiopharma; POINT Biopharma; RayzeBio
 
Jeremie Calais
Honoraria - Advanced Accelerator Applications; Curium Pharma; EXINI Diagnostics; Novartis; Progenics; Radiomedix
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Blue Earth Diagnostics; Curium Pharma; GE Healthcare; Janssen; Lantheus Medical Imaging; Novartis; POINT Biopharma; Progenics; Radiomedix; Sanofi; SOFIE; Telix Pharmaceuticals
Speakers' Bureau - Lantheus Medical Imaging
Research Funding - Progenics